Latest news in cancer
Claudin 18.2 and its role in advanced gastric cancers
Claudin 18.2 (CLDN18.2) is a tight junction protein predominantly found in gastric epithelial cells. In gastric cancers, its expression becomes aberrant,...
Accelerated approval is granted by FDA to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial...
Capmatinib is approved for metastatic non-small cell lung cancer
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial...
Darolutamide tablets is approved by FDA for metastatic hormone-sensitive prostate cancer
August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration...
Fam-trastuzumab deruxtecan-nxki is approved by FDA for HER2-low breast cancer
August 2022: For adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH) breast cancer who have received prior chemotherapy in the...
Crizotinib is approved by FDA for ALK-positive inflammatory myofibroblastic tumor
July 2022: Crizotinib (Xalkori, Pfizer Inc.) was granted approval by the Food and Drug Administration (FDA) for the treatment of adult and paediatric...
A memorandum of understanding (MOU) has been signed by GenScript ProBio to form a strategic partnership with ACT Therapeutics to develop new CAR-T cell therapies
July 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a...
CAR T-Cell therapy market will grow at phenomenal rate in next 8 years
July 2022: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29 billion...
Stanford researchers modified anti-cancer CAR-T cells so they can be controlled with an oral drug
June 2022: According to the findings of a study that was just recently published by Stanford Medicine in mice, a cancer treatment that makes use of a...
New CAR T-cell therapy showed acceptable safety profile in solid tumors
April 2022: According to preliminary data from a phase I/II clinical trial that was presented during the AACR Annual Meeting 2022, which was held from April...
Korean homegrown CAR T-Cell therapy is on the way
Nov 2021: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to...
Lisocabtagene maraleucel is approved by FDA for second-line treatment of large B-cell lymphoma
July 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been approved by the Food and Drug Administration for adult patients with large...
Dabrafenib in combination with trametinib is approved by FDA for unresectable or metastatic solid tumors with BRAF V600E mutation
July 2022: Dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) received accelerated approval from the Food and Drug Administration for the...
All participants in a small cancer trial achieved complete remission
June 2022: A small study of rectal cancer patients yielded extraordinary results: 100 percent of the individuals were in remission. The results were published...
Tisagenlecleucel is approved by FDA for relapsed or refractory follicular lymphoma
June 2022: After two or more lines of systemic therapy, the FDA awarded tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) expedited approval...
Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy is approved by FDA for first-line esophageal squamous cell carcinoma indications
June 2022: For the first-line therapy of individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), the Food and Drug Administration...
Ivosidenib in combination with azacitidine is approved for newly diagnosed acute myeloid leukemia
June 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine has been approved by the Food and Drug Administration for newly...
Azacitidine is approved by FDA for newly diagnosed juvenile myelomonocytic leukemia
June 2022: The FDA has approved the drug azacitidine (Vidaza, Celgene Corp.) for children with newly diagnosed juvenile myelomonocytic leukaemia (JMML). The...
New treatment identified for low grade and serous ovarian cancer
May 2022: Trametinib may become a new standard of care for recurring, low-grade serous ovarian cancer (Mekinist). According to study findings published in the...
Weight loss is linked to decreased risk of colon and rectal polyps
May 2022: According to study findings published February 1 in the Journal of the National Cancer Institute, overweight or obese adults who lose more than 5...
T-cell therapy for gastric, liver and pancreatic cancer
May 2022: T-cell therapy has begun a vigorous attack on digestive system malignancies, and T-cell immunotherapy has triumphed over refractory tumours like...
FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumors
May 2022: FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumours in a CAR-NK clinical trial. The FDA...
Patient experience of CAR T-cell therapy suffering from acute lymphoblastic leukemia
May 2022: Matthew is a 27-year-old patient with Acute Lymphoblastic Leukemia who was diagnosed in 2015. Unfortunately, the standard treatment of chemotherapy...
CAR T-Cell therapy for mantle cell lymphoma (MCL)
Induction therapy followed by stem cell transplantation has maintained a role in the treatment of mantle cell lymphoma (MCL), according to James Gerson, MD,...
Fam-trastuzumab deruxtecan-nxki is approved by FDA for breast cancer
April 2022: Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the...
Pluvicto is approved by FDA for metastatic castration-resistant prostate cancer
April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis...
Pembrolizumab is approved for advanced endometrial carcinoma
April 2022: Pembrolizumab (Keytruda, Merck) was approved by the Food and Drug Administration as a single agent for patients with advanced endometrial...
First LAG-3-Blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), is approved by FDA for patients with unresectable or metastatic melanoma
April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of...
JW Therapeutics’ IND is cleared by China NMPA for CAR T-Cell therapy in large B-Cell lymphoma
China’s National Medical Products Administration (NMPA) has approved JW Therapeutics’ investigational new drug (IND) application for a key clinical...
Can CAR T-Cell manufacturing time be reduced to just one day?
April 2022: Normally, the cell manufacturing procedure for CAR T-cell therapy takes nine to fourteen days; however, researchers at the University of...
CAR T-Cell therapy in solid tumors – A research study
March 2022: Blood vessels are supposed to behave like trees, pouring oxygen into tissues in order for them to flourish and immune cells to clean infections...
CAR T- cell therapy for breast cancer is on the cards
March 2022: According to researchers at the UNC Lineberger Comprehensive Cancer Center, adding a tiny chemical to a treatment process called chimeric antigen...
Childhood leukemia and its treatment
Leukemia in childhood Leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. Most childhood leukemias are acute...
CARVYKTI (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma
March 2022: According to Johnson & Johnson, a therapy developed by the company and its China-based partner Legend Biotech Corp to treat a kind of white...
High Intensity Focused Ultrasound
March 2022: HIFU (High Intensity Focused Ultrasound) is a cutting-edge therapy that uses focused, high-energy ultrasound waves to heat and kill cancerous parts...
CAR-T Cell therapy could be made safer and more widely available with a few adjustments
March 2022: A revolutionary approach to CAR-T Cell therapy has the potential to overturn what has become a medical axiom: that the treatment’s remarkable...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.